Investing

Neurogene : NGNE

NGNE

Stock Data

$26.85

$0.76 (2.91%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Neoleukin Therapeutics Inc, based in New York, focuses on creating genetic medicines to transform the lives of patients and families dealing with neurological diseases. Their innovative work includes NGN-401, a promising gene therapy aimed at combating Rett syndrome, and NGN-101, designed to tackle neuronal ceroid lipofuscinosis subtype 5 batten disease. Their dedication to addressing these challenging conditions highlights their commitment to advancing medical science and improving patient care.

All Neurogene Articles

1 Article

Lee Jackson | Feb 27, 2026 at 7:59 AM EST

Here Are Friday’s Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner Bros. Discovery, and More

Pre-Market Stock Futures: The futures are trading lower as we get set to conclude one of the zaniest trading weeks…